 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
84 News |  |
| «12 |
- ||||| brilanestrant (GDC-0810) / Roche
New P2 trial: HydranGea: A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy (clinicaltrials.gov) - Oct 7, 2015
P2, N=152, Not yet recruiting, Sponsor: Genentech, Inc.
- brilanestrant (GDC-0810) / Roche
Phase classification, Enrollment change, Trial initiation date, Trial primary completion date: A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Jan 15, 2015
P2, N=141, Recruiting, Sponsor: Genentech, Inc.
Phase classification: P1 --> P2 | N=72 --> 141 | Initiation date: Mar 2013 --> Dec 2014 | Trial primary completion date: Mar 2015 --> Jul 2017
- ||| brilanestrant (GDC-0810) / Roche
New P1 trial: A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Apr 2, 2013
P1, N=72, Recruiting, Sponsor: Seragon Pharmaceuticals, Inc.